BYQLOVI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Byqlovi, and what generic alternatives are available?
Byqlovi is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in BYQLOVI is clobetasol propionate. There is one drug master file entry for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Byqlovi
A generic version of BYQLOVI was approved as clobetasol propionate by COSETTE PHARMS NC on February 16th, 1994.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BYQLOVI?
- What are the global sales for BYQLOVI?
- What is Average Wholesale Price for BYQLOVI?
Summary for BYQLOVI
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 1 |
| What excipients (inactive ingredients) are in BYQLOVI? | BYQLOVI excipients list |
| DailyMed Link: | BYQLOVI at DailyMed |
Recent Clinical Trials for BYQLOVI
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Research Insight LLC | PHASE4 |
Pharmacology for BYQLOVI
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for BYQLOVI
BYQLOVI is protected by two US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | BYQLOVI | clobetasol propionate | SUSPENSION/DROPS;OPHTHALMIC | 218158-001 | Mar 4, 2024 | RX | Yes | Yes | 11,376,262 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Harrow Eye | BYQLOVI | clobetasol propionate | SUSPENSION/DROPS;OPHTHALMIC | 218158-001 | Mar 4, 2024 | RX | Yes | Yes | 10,588,913 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Harrow Eye | BYQLOVI | clobetasol propionate | SUSPENSION/DROPS;OPHTHALMIC | 218158-001 | Mar 4, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BYQLOVI
See the table below for patents covering BYQLOVI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2016262185 | ⤷ Start Trial | |
| Brazil | 112017024000 | ⤷ Start Trial | |
| Canada | 2985171 | ⤷ Start Trial | |
| China | 107613985 | ⤷ Start Trial | |
| European Patent Office | 3295943 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch